Nurix Therapeutics Inc [NRIX] stock is trading at $17.68, up 2.79%. An important factor to consider is whether the stock is rising or falling in short-term value. The NRIX shares have gain 15.33% over the last week, with a monthly amount glided 51.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Mizuho started tracking the stock with Outperform rating on October 21, 2025, and set its price target to $24. On March 17, 2025, Leerink Partners initiated with a Market Perform rating and assigned a price target of $16 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $35 on December 10, 2024. BMO Capital Markets initiated its recommendation with an Outperform and recommended $35 as its price target on December 06, 2024. UBS started tracking with a Buy rating for this stock on October 24, 2024, and assigned it a price target of $35. In a note dated October 11, 2024, Jefferies initiated a Buy rating and provided a target price of $41 on this stock.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $8.18 and $23.00 over the past year. Currently, Wall Street analysts expect the stock to reach $27.11 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $17.68 at the most recent close of the market. An investor can expect a potential return of 53.34% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 83.69M for the trailing twelve months, which represents a drop of -37.29%. Gross Profit Margin for this corporation currently stands at -1.63% with Operating Profit Margin at -3.19%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.47, Equity is -0.54 and Total Capital is -0.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.36 points at the first support level, and at 17.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.90, and for the 2nd resistance point, it is at 18.11.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 5.35. On the other hand, the Quick Ratio is 5.35, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 21.41, the price to book ratio is 3.65.
Transactions by insiders
Recent insider trading involved Ring Christine, Chief Legal Officer, that happened on Nov 24 ’25 when 37600.0 shares were sold. Officer, CHRISTINE RING completed a deal on Nov 24 ’25 to buy 37600.0 shares. Meanwhile, Chief Financial Officer van Houte Hans sold 6284.0 shares on Nov 03 ’25.
